ThromboGenics granted 6-month review for eye treatment
This article was originally published in Scrip
Executive Summary
ThromboGenics officially revealed that the US FDA has accepted for review the firm's biologics license application (BLA) for ocriplasmin intravitreal as a treatment for symptomatic vitreomacular adhesion (VMA), including macular hole, a progressive condition that if left untreated generally leads to significant visual distortion, deterioration in vision and in some cases central blindness.